Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
11.88
-0.50 (-4.04%)
May 14, 2026, 4:00 PM EDT - Market closed
Xencor Employees
Xencor had 260 employees as of December 31, 2025. The number of employees increased by 10 or 4.00% compared to the previous year.
Employees
260
Change (1Y)
10
Growth (1Y)
4.00%
Revenue / Employee
$374,462
Profits / Employee
-$663,158
Market Cap
880.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 10 | 4.00% | 260 | 0 |
| Dec 31, 2024 | 250 | -30 | -10.71% | 250 | 0 |
| Dec 31, 2023 | 280 | -1 | -0.36% | 280 | 0 |
| Dec 31, 2022 | 281 | 27 | 10.63% | 281 | 0 |
| Dec 31, 2021 | 254 | 52 | 25.74% | 254 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Geron | 258 |
| Sana Biotechnology | 142 |
| Absci | 140 |
| Janux Therapeutics | 108 |
| ORIC Pharmaceuticals | 104 |
| Annexon | 93 |
| Design Therapeutics | 54 |
XNCR News
- 2 days ago - Xencor Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Xencor price target raised to $14 from $13 at JPMorgan - TheFly
- 8 days ago - Xencor reports Q1 EPS ($1.71), consensus (75c) - TheFly
- 8 days ago - Xencor Reports First Quarter 2026 Financial Results - Business Wire
- 9 days ago - Xencor Transcript: Digestive Disease Week Conference - Transcripts
- 10 days ago - Xencor to host webcast to discuss XmAb942, XmAb412 data presentations - TheFly
- 10 days ago - Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW - Business Wire
- 7 weeks ago - JPMorgan downgrades Xencor on lack of ‘needle-moving’ catalysts - TheFly